LifeVantage Reports 25.3% Revenue Decline in Third Quarter, Net Income Down 60.7%

LifeVantage Corporation reported its financial results for the three and nine months ended March 31, 2026, revealing a significant decline in revenue and profitability compared to the previous fiscal period. The company generated net revenue of $43.7 million for the third quarter, down 25.3% from $58.4 million in the same quarter of 2025. For the nine-month period, revenue decreased to $140.2 million from $173.4 million, representing a 19.1% decline. The net income for the third quarter was $1.4 million, a decrease of 60.7% from $3.5 million in the prior year, while net income for the nine months fell to $3.8 million from $7.8 million.

The decline in revenue was primarily attributed to decreased sales of the MindBody GLP-1 System®, which saw a drop of $9.6 million and $20.1 million for the three and nine months ended March 31, 2026, respectively. This decline was partially offset by sales from the recently acquired LoveBiome product line, which contributed to the overall revenue. The company also experienced a reduction in active accounts, with total active independent consultants and customers decreasing by 13.5% and 27.3%, respectively, compared to the previous year.

In terms of operational metrics, LifeVantage's total active accounts fell to 109,000 as of March 31, 2026, down from 140,000 a year earlier. The Americas region accounted for a significant portion of the decline, with active independent consultants dropping from 35,000 to 30,000, and active customers decreasing from 74,000 to 51,000. The Asia/Pacific and Europe region also saw a reduction in active accounts, with independent consultants decreasing from 17,000 to 15,000.

Strategically, LifeVantage completed the acquisition of LoveBiome in October 2025, which is expected to enhance its product offerings in the microbiome care and wellness sector. The company has also launched a new compensation plan for its independent consultants, aimed at improving sales performance. Despite the challenges faced in the current fiscal period, LifeVantage remains focused on expanding its product lines and geographic reach, with plans to continue refining its offerings and marketing strategies.

Looking ahead, LifeVantage anticipates that its ongoing efforts to enhance product development and marketing initiatives will support revenue growth. The company maintains a liquidity position of $12.5 million as of March 31, 2026, down from $20.2 million at the end of the previous fiscal year. Management believes that current cash balances and future cash flow from operations will be sufficient to meet its obligations for at least the next 12 months, although they are prepared to consider additional funding options if necessary.